NASDAQ · NRC

NRC Health

$21.04 +$0.21 (+1.01%) 1D After hours

Key Metrics

$469.44M
Market cap
P/E · TTM
$1.25M
Revenue · TTM
−$2.57M
Net income
EPS · TTM $-0.11
Dividend yield
Free cash flow
Beta · 1Y 0.53
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Feb 17
    From its Feb 2 high, the share price fell 45%.

    Peak close $21.90 on Feb 2; trough close $12.03 on Feb 17. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -45%
  • Feb 4
    The stock moved -13.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 4
  • Feb 3
    The stock moved -19.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 3

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$469.44M
Enterprise value$540.91M
Shares outstanding22.5M
52-wk range$11.01 – $23.00
Avg volume · 20D64.7K
Net cash −$71.47M
Book value / share$0.59
IndustryServices-Commercial Physical & Biological Research
ExchangeNASDAQ
About NRC Health
IPO dateOct 10, 1997
Employees357

NRC Health operates as a humanized healthcare and support organization. Its platform includes Listen, Understand, and Improve. The group provides solutions for Patient, Consumer, Employee, and Market experiences.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S374.95
P/FCF
EV/EBITDA
EV/Sales432.04
Graham №

Profitability

Gross
Operating -267.1%
Net -204.9%
FCF
ROE / ROIC -11.5% · —

Financial Health

Current ratio0.52
Quick ratio
Debt / equity5.48
Debt / EBITDA
Net cash −$71.47M
Working capital−$18.49M

Cash Flow · TTM

Operating CF
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

0 / 9
Weak fundamentals · 0 of 9 signals passing

Altman Z-Score

1.9
Grey zone (1.81–2.99) · monitor

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings